IOLCP212.00

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersMOREPENLABFDCINNOVACAPORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹6,223 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,132.82,079.22,319.12,523.6
Other Income30.122.421.422.2
Total Income2,162.92,101.62,340.42,545.8
Expenses
+ Cost of Materials Consumed1,435.11,358.31,501.61,631.8
+ Purchases of Stock-in-Trade0.20.04.04.8
+ Changes in Inventories-38.333.5-18.5-35.7
+ Employee Benefit Expense201.0216.6248.3261.8
+ Finance Costs16.114.814.614.0
+ Depreciation & Amortisation62.972.080.281.8
+ Other Expenses304.2268.5314.7350.6
Total Expenses1,981.21,963.72,144.92,309.1
EBITDA230.6202.3269.0310.3
EBIT167.7130.3188.7228.5
Profit
PBT before Exceptional Items181.7138.0195.6236.8
+ Exceptional Items0.00.0-11.2-11.2
Pretax Income181.7138.0184.4225.5
+ Current Tax37.024.740.651.8
+ Deferred Tax10.212.26.25.6
Tax Expense47.236.946.757.4
Net Income134.4101.1137.6168.1
+ Net Income — Continuing Ops134.4101.1137.6168.1
+ Other Comprehensive Income-1.3-1.42.62.2
Total Comprehensive Income133.199.6140.2170.3
Per Share
Basic EPS22.903.444.695.73
Diluted EPS22.903.444.695.73
Other Comprehensive Income — detail
+ Other Comprehensive Income-1.42.62.2
+ Items NOT to be Reclassified to P&L-1.7-1.02.63.1
+ Tax on Items NOT to be Reclassified-0.20.70.8
+ Tax on Items NOT to be Reclassified — alt tag-0.4
+ Items to be Reclassified to P&L-1.00.9-0.2
+ Tax on Items to be Reclassified-0.20.2-0.0
+ Tax on Items to be Reclassified — alt tag0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations22.903.444.695.73
Diluted EPS — Continuing Operations22.903.444.695.73
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit735.8687.4832.0922.8
Gross Margin %34.5033.0635.8736.57
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)181.7138.0195.6236.8
− Exceptional Items (reconciliation)0.00.0-11.2-11.2
Net Income Adj (tax-effected)134.4101.1146.0176.5
EPS Adj22.903.444.986.01
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.002.002.002.00
Paid Up Equity Capital58.758.758.758.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.